These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease. Gamez-Gonzalez LB, Moribe-Quintero I, Cisneros-Castolo M, Varela-Ortiz J, Muñoz-Ramírez M, Garrido-García M, Yamazaki-Nakashimada M. Pediatr Int; 2018 Sep; 60(9):781-790. PubMed ID: 29888440 [Abstract] [Full Text] [Related]
10. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Baer AZ, Rubin LG, Shapiro CA, Sood SK, Rajan S, Shapir Y, Romano A, Bierman FZ. Arch Pediatr Adolesc Med; 2006 Jul; 160(7):686-90. PubMed ID: 16818833 [Abstract] [Full Text] [Related]
11. [Kawasaki disease shock syndrome: a case report]. Vieni G, Pusceddu S, Bruno I, Ragni L, Marchetti F. G Ital Cardiol (Rome); 2018 Feb; 19(2):111-114. PubMed ID: 29531383 [Abstract] [Full Text] [Related]
12. Outcomes of Kawasaki Disease: A Single-Center Experience. Uysal F, Bostan OM, Celebi S, Uysal B, Hamitoglu S, Cil E. Clin Pediatr (Phila); 2015 Jun; 54(6):579-84. PubMed ID: 25475592 [Abstract] [Full Text] [Related]
13. Kawasaki disease in Sicily: clinical description and markers of disease severity. Maggio MC, Corsello G, Prinzi E, Cimaz R. Ital J Pediatr; 2016 Nov 02; 42(1):92. PubMed ID: 27806720 [Abstract] [Full Text] [Related]
14. Recognition of a Kawasaki disease shock syndrome. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, Watson VE, Best BM, Burns JC. Pediatrics; 2009 May 02; 123(5):e783-9. PubMed ID: 19403470 [Abstract] [Full Text] [Related]
15. Kawasaki disease with shock as the primary manifestation: How to distinguish from toxic shock syndrome?: A case report and literature review. Wang W, Wang H, Wang H, Cheng J. Medicine (Baltimore); 2024 Aug 02; 103(31):e39199. PubMed ID: 39093792 [Abstract] [Full Text] [Related]
16. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Li Y, Zheng Q, Zou L, Wu J, Guo L, Teng L, Zheng R, Jung LKL, Lu M. Pediatr Rheumatol Online J; 2019 Jan 05; 17(1):1. PubMed ID: 30611297 [Abstract] [Full Text] [Related]
17. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997 [Abstract] [Full Text] [Related]
18. Characteristics of children with Kawasaki disease requiring intensive care: 10 years' experience at a tertiary pediatric hospital. Kuo CC, Lee YS, Lin MR, Hsia SH, Chen CJ, Chiu CH, Hwang MS, Huang YC. J Microbiol Immunol Infect; 2018 Apr 17; 51(2):184-190. PubMed ID: 27591913 [Abstract] [Full Text] [Related]
19. Clinical manifestations of Kawasaki disease shock syndrome: a case-control study. Chen PS, Chi H, Huang FY, Peng CC, Chen MR, Chiu NC. J Microbiol Immunol Infect; 2015 Feb 17; 48(1):43-50. PubMed ID: 23927822 [Abstract] [Full Text] [Related]
20. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. PLoS One; 2015 Feb 17; 10(12):e0144603. PubMed ID: 26658843 [Abstract] [Full Text] [Related] Page: [Next] [New Search]